InvestorsHub Logo
Followers 156
Posts 6367
Boards Moderated 1
Alias Born 08/06/2004

Re: None

Tuesday, 05/10/2022 5:53:42 PM

Tuesday, May 10, 2022 5:53:42 PM

Post# of 462873
On the Alzheimer Ph-2b/3 trial he said there was over 90% that elected to continue. That is a huge number for a CNS drug.

That says A2-73 has helping a great majority at over 90% and will likely result in a NDA approval when the time comes.

I did not hear him suggest any damn 'stoppers' as I call them, as they are common with Biotechs.

I like what I heard, he sounded confident concerning the various trials.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News